Refine by
Locations
- Europe
- Albania
- Andorra
- Austria
- Belarus
- Belgium
- Bosnia & Herzegovina
- Bulgaria
- Croatia
- Cyprus
- Czech Republic
- Denmark
- Estonia
- Faroe Islands
- Finland
- France
- Germany
- Greece
- Hungary
- Iceland
- Ireland
- Italy
- Kosovo
- Latvia
- Liechtenstein
- Lithuania
- Luxembourg
- Macedonia
- Malta
- Moldova
- Monaco
- Montenegro
- Netherlands
- Northern Ireland
- Norway
- Poland
- Portugal
- Romania
- San Marino
- Serbia
- Slovakia
- Slovenia
- Spain
- Sweden
- Switzerland
- Turkey
- Ukraine
- United Kingdom
- Vatican City
Eluting Stent Equipment Supplied In Europe
19 equipment items found
Manufactured by:LVD Biotech based inSant Vicenç dels Horts, SPAIN
We manufacture DES Drug Delivery with proprietary delivery systems. We handle several drugs and have shown controlled release over a prolonged period enabling healing of the surrounding vascular tissue and endothelial layer. ...
Manufactured by:Concept Medical Inc. based inTampa, FLORIDA (USA)
Drug is coated on the abluminal side only. Leading to mono directional drug release & less systemic exposure of drug which leads to faster ...
Manufactured by:Arterius Limited based inLeeds, UNITED KINGDOM
Arterius has developed a polymer-based bioresorbable scaffold (or “BRS”) ArterioSorb™ that is intended to: Match the ease of delivery of Bare Metal Stent (BMS) and Drug Eluting Stent (DES); Come in a range of sizes and lengths. Provide equivalent mechanical performance (radial strength) to the best-in-classDrug ...
by:Tryton Medical, Inc. based inDurham, NORTH CAROLINA (USA)
The Tryton Side Branch Stent is deployed in the side branch artery using a standard single-wire, balloon-expandable stent delivery system. The open architecture of the Tryton stent allows for integration of a conventional drug eluting stent for the main ...
Manufactured by:Translumina GmbH based inHechingen, GERMANY
The Translumina Yukon Choice PC drug-eluting stent, coated with Rapamycin (Sirolimus) and the biodegradable component polylactide (PLA), has an excellent history of pre-clinical and long-term clinical ...
Manufactured by:Translumina GmbH based inHechingen, GERMANY
The Translumina Yukon drug-eluting stent product family, coated with Rapamycin (Sirolimus) and the biodegradable component polylactide (PLA), has an excellent history of pre-clinical and long-term clinical ...
Manufactured by:P+F Products + Features GMBH based inVienna, AUSTRIA
The EFIL+ Sirolimus Eluting Stent System is a combination product comprised of two regulated components: a device (a coronary stent system) and a drug product (a formulation of Sirolimus contained in a polymer coating) pre mounted on balloon catheter between two platinum iridium radio opaque marker bands. EFIL+ uses a validated formulation of ...
Manufactured by:Sahajanand Medical Technologies Ltd. based inSurat, INDIA
Supraflex Cruz is an amalgamation of the best-in-class features like lowest strut thickness (60 μm), biodegradable polymer and offers an extensive size ...
Manufactured by:MicroPort Scientific Corporation based inShanghai, CHINA
Extraordinary Deliverability. Ultra Low Profile. Target Eluting Technology of ...
Manufactured by:MicroPort Scientific Corporation based inShanghai, CHINA
CoCr Stent Platform. Reliable durable polymer-Styrene Butylenes Styrene. Uniform sine wave design provides uniform support strength and ...
Manufactured by:MicroPort Scientific Corporation based inShanghai, CHINA
TARGET All Comers Trial: 1,656 Patients from 20 sites in Europe. 1:1 RCT Real World open-label, non-inferiority trial Primary endpoint: TLF @12 months. Confirms that the Firehawk®, a low dose sirolimus eluting biodegradable polymer DES, is safe. and effective across a broad spectrum of patient and lesion complexity. ...
Manufactured by:OrbusNeich Medical Company Ltd. based inShatin, N.T., CHINA
The Pro-Healing DES Designed for rapid vessel healing and superior clinical ...
Manufactured by:Tsunamed, Part of Q3 Medical Group based inWinsen, GERMANY
The MAGMA Rapamycin-Eluting Coronary Stent System is the first carbonized stent (Inert Carbon Technology) with a completely biodegradable polymer coating which contains Rapamycin (Rapasorb™) as a highly effective drug for preventing thrombotic and re-stenotic ...
Manufactured by:Stron Medical, Part of Q3 Medical Group based inWinsen, GERMANY
The GALAXY Rapamycin-Eluting Coronary Stent System is the first carbonized stent (Inert Carbon Technology) with a completely biodegradable polymer coating which contains Rapamycin (Rapasorb™) as a highly effective drug for preventing thrombotic and re-stenotic ...
Manufactured by:amg International GmbH based inWinsen, GERMANY
The ITRIXII Sirolimus-Eluting Coronary Stent Implantation System is the first carbonized stent (Inert Carbon Technology) with a completely biodegradable polymer coating which contains Sirolimus (Rapasorb™) as a highly effective drug for preventing thrombotic and re-stenotic ...
Manufactured by:CARDIONOVUM GmbH based inBonn, GERMANY
Unmatched XLIMUS clinical performance. The ultimate DES for complex artery lesions. XLIMUS is considered as the ultimate coronary DES stent system to treat complex coronary artery disease by reaching and crossing the most challenging ...
Manufactured by:Becton Dickinson and Company (BD) based inFranklin Lakes, NEW JERSEY (USA)
Tepha is developing fully absorbable stents and coatings made from TephaFLEX® material. This could allow for local drug elution while leaving no permanent residual polymer, which might address the issue of late stent thrombosis with current DESs. In addition, Tepha is developing fully absorbable polymer stents containing ...
Manufactured by:Concept Medical Inc. based inTampa, FLORIDA (USA)
ABLUMINUS DES+ designed by propriety ENVISOLUTION technology in a way that address the unmet clinical needs specially in Diabetes Mellitus and Acute Myocardial infarction patients with Coronary Artery Disease. ABLUMINUS DES+ Receives on-label indication for Diabetes Mellitus and Acute Myocardial infarction. ...
Manufactured by:Veryan Medical Ltd. based inHorsham, UNITED KINGDOM
The Challenge: Peripheral Arterial Disease. People are living longer and with an increase in the incidence of obesity, diabetes and other contributing factors, claudication may cause substantial tissue changes and, in some scenarios, can lead to amputation and even death. The peripheral stent market is forecast to grow to $2 billion by 2024 driven by technological advances, an ageing population ...